Cannabis-Like Compounds From Other Plants Show Promise Against Drug-Resistant Epilepsy

Magnolol and amorfrutin 2, structurally similar to cannabinoids but from non-cannabis plants, demonstrated antiseizure activity in mouse models of drug-resistant Dravet and Lennox-Gastaut syndrome.

Yip, Ka Lai et al.·Epilepsia·2025·Moderate Evidencepreclinical
RTHC-08001PreclinicalModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
preclinical
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Magnolol reduced seizures in both Dravet (Scn1a+/-) and Lennox-Gastaut (Gabrb3+/D120N) mouse models and had excellent brain penetration (brain-to-plasma ratio 7.56). Both compounds inhibited T-type calcium channels but had no specific cannabinoid receptor activity.

Key Numbers

Magnolol brain-to-plasma ratio: 7.56. Honokiol: 3.55. Amorfrutin 2: 0.06. Amorfrutin 2 and magnolol increased seizure threshold in Scn1a+/- mice and reduced hindlimb extension in MES test.

How They Did This

Preclinical study testing three cannabis-like compounds (amorfrutin 2, honokiol, magnolol) in genetic mouse models of Dravet and Lennox-Gastaut syndrome, with pharmacokinetic profiling and molecular pharmacology at CB receptors and T-type calcium channels.

Why This Research Matters

CBD is already FDA-approved for these epilepsies, but not all patients respond. Finding structurally related compounds from non-cannabis sources that work through different mechanisms (T-type calcium channels rather than CB receptors) could expand treatment options.

The Bigger Picture

Nature contains many cannabinoid-like molecules beyond cannabis. Exploring these structural relatives could yield new antiseizure drugs without the regulatory and social complexities of cannabis-derived medicines.

What This Study Doesn't Tell Us

Mouse epilepsy models don't perfectly replicate human seizure disorders. These are early-stage findings needing extensive development. Magnolol's non-cannabinoid mechanism means it may have different side effect profiles.

Questions This Raises

  • ?Could magnolol be developed into a clinical antiseizure drug?
  • ?Would combining it with CBD provide additive benefits through complementary mechanisms?

Trust & Context

Key Stat:
Evidence Grade:
Well-designed preclinical study using clinically relevant genetic models, but compounds need extensive development before clinical application.
Study Age:
Recent drug discovery study opening new avenues for antiseizure medications inspired by cannabinoid structures.
Original Title:
Cannabinoid-like compounds found in non-cannabis plants exhibit antiseizure activity in genetic mouse models of drug-resistant epilepsy.
Published In:
Epilepsia, 66(1), 303-314 (2025)
Database ID:
RTHC-08001

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Are these compounds found in cannabis?

No — they're structurally similar to cannabinoids but come from other plants. Magnolol comes from magnolia bark, and amorfrutin 2 comes from Amorpha fruticosa (false indigo).

How do they compare to CBD for epilepsy?

They work through a different mechanism (T-type calcium channels rather than cannabinoid receptors), which could make them effective for patients who don't respond to CBD. They're still in early preclinical stages.

Read More on RethinkTHC

Cite This Study

RTHC-08001·https://rethinkthc.com/research/RTHC-08001

APA

Yip, Ka Lai; Udoh, Michael; Sharman, Laura A; Harman, Thomas; Bedoya-Pérez, Miguel; Anderson, Lyndsey L; Banister, Samuel D; Arnold, Jonathon C. (2025). Cannabinoid-like compounds found in non-cannabis plants exhibit antiseizure activity in genetic mouse models of drug-resistant epilepsy.. Epilepsia, 66(1), 303-314. https://doi.org/10.1111/epi.18177

MLA

Yip, Ka Lai, et al. "Cannabinoid-like compounds found in non-cannabis plants exhibit antiseizure activity in genetic mouse models of drug-resistant epilepsy.." Epilepsia, 2025. https://doi.org/10.1111/epi.18177

RethinkTHC

RethinkTHC Research Database. "Cannabinoid-like compounds found in non-cannabis plants exhi..." RTHC-08001. Retrieved from https://rethinkthc.com/research/yip-2025-cannabinoidlike-compounds-found-in

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.